Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vanadium - Medesis Pharma

Next Previous
Search
Drug Profile

Vanadium - Medesis Pharma

Alternative Names: NP-01 - Medesis Pharma

Latest Information Update: 28 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medesis Pharma
  • Class Heavy metals; Transition elements; Vanadium compounds
  • Mechanism of Action GLUT4 stimulants; Insulin receptor modulators; Mitogen-activated protein kinase modulators; Phosphatidylinositol 3 kinase gamma modulators; Protein tyrosine phosphatase inhibitors; Ras protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in France (Buccal)
  • 07 Jan 2020 Phase I development is ongoing in France (Medesis Pharma Pipeline, January 2020)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Type 2 diabetes mellitus (In volunteers) in France (Buccal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top